权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NETWORK OF PEDIATRIC PHARMACOLOGY RESEARCH UNITS

儿科药理学研究单位网络

基本信息

批准号：
6627368
负责人：
Michael Thomas Brady
金额：
$ 35.23万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
1994
资助国家：
美国
起止时间：
1994-01-01 至 2003-12-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/6627368
关键词：
age difference analgesics child (0-11) clinical research clinical trials cooperative study drug adverse effect drug metabolism drug screening /evaluation human subject human therapy evaluation pediatric pharmacology pediatrics pharmacokinetics

项目摘要

Pediatric drug trials are needed but are difficult to perform. Yet, Children's Hospital, Columbus has successfully completed hundreds of trials by providing the resources necessary to overcome the ethical, financial, and practical problems associated with such studies. Resources which are available include: a) active Clinical Pharmacology and Clinical Pharmacy Divisions, b) a Pediatric Clinical Study Center (P-CSC), c) a Pediatric Pharmacology Research Unit (PPRU), d) a university General Clinical Research Center (GCRC), e) basic and clinical investigators with proven track records conducting pharmaceutical research, f) a large pediatric training program, g) a supportive administrative and scientific staff and structure, h) large, representative pediatric study populations, and i) sophisticated state-of-the-art technology. Resources are located in well-designed research space and tertiary-care clinical facilities with excellent community, hospital, and academic support. A plan is proposed to build on our past PPRU success by continuing as a member of an expanded NICHD pediatric pharmacology research "Network". The Columbus PPRU would continue to provide training and serve as a resource to federal, pharmaceutical, and other entities for the planning, conduct, and analysis of pediatric drug studies. Pediatric bioavailability, formulations, drug metabolism, pharmacokinetic (PK), pharmacodynamic (PD), safety and efficacy studies would all be performed. The PPRU Network objective is to increase the number and variety of medications that are FDA-approved for use in children. The ultimate goal is to provide the data necessary for all drugs to be labeled for appropriate use in infants and children. Available resources, previous PPRU experience, as well as clinical trial and training activities are reviewed to illustrate how this PPRU would guarantee rapid progress toward this objective. Studies performed would be consistent with the mission of the NICHD and the needs of practitioners and their pediatric patients. A specific example is given of an analgesic/antipyretic trial proposed for completion by the Network to illustrate the ability of this PPRU to recruit sponsors, to design studies, to incorporate the unique strengths of individual PPRU Network members, and to maximize the scientific value of the results produced. The resources available and the applicant's proven ability to conduct pediatric trials in a variety of pediatric populations both provide the NICHD the opportunity to "leverage" its investment in the Columbus PPRU. This would enhance the pace of pediatric drug development, increase the number of trained pediatric pharmacologists available, and improve both the amount and quality of pediatric pharmacology research produced.

儿科药物试验是必要的，但很难执行。然而，哥伦布儿童医院通过提供必要的资源来克服与此类研究相关的伦理、财务和实际问题，成功地完成了数百项试验。现有资源包括：a）活跃的临床药理学和临床药学部门，B）儿科临床研究中心（P-CSC），c）儿科药理学研究单位（PPRU），d）大学综合临床研究中心（GCRC），e）具有进行药物研究的良好记录的基础和临床研究者，f）大型儿科培训计划，g）支持性的行政和科学人员和结构，h）大型的、有代表性的儿科研究人群，以及i）先进的尖端技术。资源位于精心设计的研究空间和三级护理临床设施中，拥有优秀的社区，医院和学术支持。一个计划是建议建立在我们过去的PPRU的成功，继续作为一个扩大的NICHD儿科药理学研究“网络”的成员。哥伦布PPRU将继续为联邦、制药和其他实体提供培训，并作为儿科药物研究规划、实施和分析的资源。将进行儿科生物利用度、制剂、药物代谢、药代动力学（PK）、药效学（PD）、安全性和疗效研究。 PPRU网络的目标是增加FDA批准用于儿童的药物的数量和种类。最终目标是为所有药物提供必要的数据，以便在婴儿和儿童中适当使用。现有的资源，以前的PPRU的经验，以及临床试验和培训活动进行审查，以说明这个PPRU将保证朝着这一目标的快速进展。进行的研究将与NICHD的使命以及从业者及其儿科患者的需求一致。一个具体的例子是镇痛药/解热药试验建议完成的网络，以说明这个PPRU招募赞助商的能力，设计研究，将个别PPRU网络成员的独特优势，并最大限度地提高所产生的结果的科学价值。现有的资源和申请人在各种儿科人群中进行儿科试验的能力都为NICHD提供了“利用”其在哥伦布PPRU的投资的机会。这将加快儿科药物开发的步伐，增加训练有素的儿科药理学家的数量，并提高儿科药理学研究的数量和质量。